Differential Effects on Intestinal Adaptation Following Exogenous Glucagon-Like Peptide 2 Therapy With and Without Enteral Nutrition in Neonatal Short Bowel Syndrome
Restricted accessResearch articleFirst published online February, 2017
Differential Effects on Intestinal Adaptation Following Exogenous Glucagon-Like Peptide 2 Therapy With and Without Enteral Nutrition in Neonatal Short Bowel Syndrome
Background: We aim to study the efficacy of exogenously administered glucagon-like peptide 2 (GLP-2) on intestinal adaptation in 2 preclinical models of neonatal short bowel syndrome (SBS) according to remnant intestinal anatomy, with and without ileum. Furthermore, we aim to determine if this adaptive effect was potentiated with enteral nutrition (EN). Methods: Neonatal piglets were block-randomized to 75% mid-intestinal (JI group, retains ileum) or distal-intestinal (JC group, has no ileum) resection or no resection (sham control) and GLP-2 treatment (11 nmol/kg/d) or saline control for 7 days. Piglets received nutrition support, either 100% parenteral nutrition (PN; 0% EN, n = 32 in total) or 80% PN + 40% EN (n = 28 in total). Adaptation was assessed by morphological and histological changes, as well as RT quantitative polymerase chain reaction of nutrient transporters and tight junctional proteins and fat absorption. Data are analyzed by 3-way analysis of variance (ANOVA) and 2-way ANOVA per EN level. Results: GLP-2 treatment lengthened villi, deepened crypts, and improved intestinal weight in the remnant intestine of JC piglets. EN was a more potent adaptive stimulus for JI piglets. Small intestinal lengthening occurred only in the JI group, when given EN. There was no difference in total fat absorption and messenger RNA expression of nutrient transporters and tight junctional proteins. Conclusions: GLP-2 administration augmented structural adaptation in JC piglets with distal intestinal resection. Given JI anatomy, further stimulation by GLP-2 treatment over innate adaptation and stimulation by EN was modest and restricted to ileum. The differential effect of GLP-2 in neonatal SBS, depending on remnant anatomy, has important implications for clinical translation and planning of clinical trials.
VanderhoofJALangnasAN. Short-bowel syndrome in children and adults. Gastroenterology. 1997;113(5):1767-1778.
2.
Quiros-TejeiraREAmentMEReyenL. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr. 2004;145(2):157-163.
3.
GouletORuemmeleF. Causes and management of intestinal failure in children. Gastroenterology. 2006;130(2)(suppl 1):S16-S28.
4.
AminSCPappasCIyengarHMaheshwariA. Short bowel syndrome in the NICU. Clin Perinatol. 2013;40(1):53-68.
5.
NightingaleJM. Management of patients with a short bowel. Nutrition. 1999;15(7-8):633-637.
6.
GutierrezIMKangKHJaksicT. Neonatal short bowel syndrome. Semin Fetal Neonatal Med. 2011;16(3):157-163.
7.
CarlsonSJChangMINandivadaPCowanEPuderM. Neonatal intestinal physiology and failure. Semin Pediatr Surg. 2013;22(4):190-194.
8.
BatraABeattieRM. Management of short bowel syndrome in infancy. Early Hum Dev. 2013;89(11):899-904.
9.
JeppesenPB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr. 2014;38(1)(suppl):8S-13S.
10.
TappendenKA. Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy. JPEN J Parenter Enteral Nutr. 2014;38(1)(suppl):14S-22S.
11.
CislerJJBuchmanAL. Intestinal adaptation in short bowel syndrome. J Investig Med. 2005;53(8):402-413.
12.
DowlingRH. Glucagon-like peptide-2 and intestinal adaptation: an historical and clinical perspective. J Nutr. 2003;133(11):3703-3707.
SondheimerJMCadnapaphornchaiMSontagMZerbeGO. Predicting the duration of dependence on parenteral nutrition after neonatal intestinal resection. J Pediatr. 1998;132(1):80-84.
15.
BuchmanALScolapioJFryerJ. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124(4):1111-1134.
16.
SpencerAUNeagaAWestB. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242(3):403-412.
17.
ThompsonJSRochlingFAWesemanRAMercerDF. Current management of short bowel syndrome. Curr Probl Surg. 2012;49(2):52-115.
18.
KellyDA. Liver complications of pediatric parenteral nutrition—epidemiology. Nutrition. 1998;14(1):153-157.
19.
GuglielmiFWBoggio-BertinetDFedericoA. Total parenteral nutrition–related gastroenterological complications. Dig Liver Dis. 2006;38(9):623-642.
20.
WalesPWChristison-LagayER. Short bowel syndrome: epidemiology and etiology. Semin Pediatr Surg. 2010;19(1):3-9.
21.
KellyDGTappendenKAWinklerMF. Short bowel syndrome: highlights of patient management, quality of life, and survival. JPEN J Parenter Enteral Nutr. 2014;38(4):427-437.
22.
WalesPWde SilvaNKimJLecceLToTMooreA. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39(5):690-695.
23.
SquiresRHDugganCTeitelbaumDH. Natural history of pediatric intestinal failure: initial report from the pediatric intestinal failure consortium. J Pediatr. 2012;161(4):723-8.e2.
24.
JavidPJMaloneFRReyesJHealeyPJHorslenSP. The experience of a regional pediatric intestinal failure program: successful outcomes from intestinal rehabilitation. Am J Surg. 2010;199(5):676-679.
25.
ModiBPLangerMChingYA. Improved survival in a multidisciplinary short bowel syndrome program. J Pediatr Surg. 2008;43(1):20-24.
26.
KosarCSteinbergKde SilvaNAvitzurYWalesPW. Cost of ambulatory care for the pediatric intestinal failure patient: one-year follow-up after primary discharge. J Pediatr Surg. 2016;51(5):798-803.
27.
DruckerDJErlichPAsaSLBrubakerPL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911-7916.
28.
TsaiCHHillMAsaSLBrubakerPLDruckerDJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol. 1997;273(1, pt 1):E77-E84.
29.
HartmannBJohnsenAHOrskovCAdelhorstKThimLHolstJJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21(1):73-80.
30.
DruckerDJYustaB. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
31.
JeppesenPB. Teduglutide for the treatment of short bowel syndrome. Drugs Today (Barc). 2013;49(10):599-614.
32.
SangildPTNeyDMSigaletDLVeggeABurrinD. Animal models of gastrointestinal and liver diseases: animal models of infant short bowel syndrome: Translational relevance and challenges. Am J Physiol Gastrointest Liver Physiol. 2014;307(12):G1147-G1168.
33.
VeggeAThymannTLundP. Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. Am J Physiol Gastrointest Liver Physiol. 2013;305(4):G277-G285.
34.
SuriMTurnerJMSigaletDL. Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome. Pediatr Res. 2014;76(4):370-377.
35.
ThymannTStollBMecklenburgL. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr. 2014;58(6):694-702.
36.
NaberhuisJKDeutschASTappendenKA. Teduglutide-stimulated intestinal adaptation is complemented and synergistically enhanced by partial enteral nutrition in a neonatal piglet model of short bowel syndrome [published online August24, 2015]. JPEN J Parenter Enteral Nutr.
37.
BrinkmanASMuraliSGHittSSolversonPMHolstJJNeyDM. Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am J Physiol Gastrointest Liver Physiol. 2012;303(5):G610-G622.
38.
BurrinDGStollBJiangR. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?Am J Clin Nutr. 2000;71(6):1603-1610.
39.
TysonJEKennedyKA. Minimal enteral nutrition for promoting feeding tolerance and preventing morbidity in parenterally fed infants. Cochrane Database Syst Rev. 2000;(2):CD000504.
40.
TurnerJMWalesPWNationPN. Novel neonatal piglet models of surgical short bowel syndrome with intestinal failure. J Pediatr Gastroenterol Nutr. 2011;52(1):9-16.
41.
HuaZTurnerJMSigaletDL. Role of glucagon-like peptide-2 deficiency in neonatal short-bowel syndrome using neonatal piglets. Pediatr Res. 2013;73(6):742-749.
42.
WykesLJBallROPencharzPB. Development and validation of a total parenteral nutrition model in the neonatal piglet. J Nutr. 1993;123(7):1248-1259.
43.
BurrinDGStollBJiangR. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol. 2000;279(6):G1249-G1256.
44.
SigaletDLde HeuvelEWallaceL. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept. 2014;188:70-80.
45.
HorwitzW, eds. Official Methods of Analysis of AOAC International. 17th ed. Gaithersburg, MD: Association of Official Analytical Chemists International; 2000.
46.
BlencoweHCousensSOestergaardMZ. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162-2172.
47.
LimDWTurnerJMWalesPW. Emerging piglet models of neonatal short bowel syndrome. JPEN J Parenter Enteral Nutr. 2015;39(6):636-643.
48.
XiaoQBousheyRPDruckerDJBrubakerPL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology. 1999;117(1):99-105.
49.
HansenCFVrangNSangildPTJelsingJ. Novel insight into the distribution of L-cells in the rat intestinal tract. Am J Transl Res. 2013;5(3):347-358.
50.
WalesPWde SilvaNKimJHLecceLSandhuAMooreAM. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40(5):755-762.
51.
RoccaASBrubakerPL. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology. 1995;136(12):5593-5599.
52.
BrubakerPLAniniY. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol. 2003;81(11):1005-1012.
53.
ShinEDEstallJLIzzoADruckerDJBrubakerPL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology. 2005;128(5):1340-1353.
54.
BrubakerPLIzzoAHillMDruckerDJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997;272(6, pt 1):E1050-E1058.
55.
CheesemanCI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol. 1997;273(6, pt 2):R1965-R1971.
56.
CheesemanCIO’NeillD. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Exp Physiol. 1998;83(5):605-616.
57.
KatoYYuDSchwartzMZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg. 1999;34(1):18-21.
58.
BenjaminMAMcKayDMYangPCCameronHPerdueMH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000;47(1):112-119.
59.
KitchenPAFitzgeraldAJGoodladRA. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol Gastrointest Liver Physiol. 2000;278(3):G425-G428.
60.
AuAGuptaASchembriPCheesemanCI. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J. 2002;367(pt 1):247-254.
61.
RamsanahieAPBergerUVZinnerMJWhangEERhoadsDBAshleySW. Effect of glucagon-like peptide-2 (GLP-2) on diurnal SGLT1 expression. Dig Dis Sci. 2004;49(11-12):1731-1737.
62.
CaniPDPossemiersSVan de WieleT. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091-1103.
63.
HsiehJLonguetCMaidaA. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 2009;137(3):997-1005.e1-4.
64.
YuCJiaGJiangY. Effect of glucagon-like peptide 2 on tight junction in jejunal epithelium of weaned pigs though MAPK signaling pathway. Asian Australas J Anim Sci. 2014;27(5):733-742.
65.
DongCXZhaoWSolomonC. The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function. Endocrinology. 2014;155(2):370-379.
66.
BurrinDGPetersenYStollBSangildP. Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J Nutr. 2001;131(3):709-712.
67.
PetersenYMBurrinDGSangildPT. GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs. Am J Physiol Regul Integr Comp Physiol. 2001;281(6):R1986-R1993.
68.
PetersenYMElnifJSchmidtMSangildPT. Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets. Pediatr Res. 2002;52(4):498-503.
JeppesenPBHartmannBThulesenJ. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806-815.
71.
JeppesenPBSanguinettiELBuchmanA. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224-1231.
72.
JeppesenPBGilroyRPertkiewiczMAllardJPMessingBO’KeefeSJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-914.
73.
JeppesenPBPertkiewiczMMessingB. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.e3.
74.
DubePEForseCLBahramiJBrubakerPL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
75.
YustaBHollandDKoehlerJA. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137(3):986-996.
76.
RowlandKJBrubakerPL. The “cryptic” mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol. 2011;301(1):G1-G8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
